Panakes Fund I

Panakes Fund I is an early-stage venture capital fund managed by Panakes Partners, an Italy-based firm founded in 2015. The fund focuses on investing in the life sciences and healthcare sectors across Europe and Israel, with particular emphasis on medical devices, diagnostics, and healthcare technology systems. Investments typically range from EUR 5 million to EUR 6 million. Leveraging a broad network of business contacts and extensive domain expertise, Panakes Partners aims to provide proactive portfolio management and foster relationships with selected industrial partners to support the growth of its portfolio companies.

Andrea Ballerini

Associate

Alessio Beverina

Co-Founder & Managing Partner

Laura Brolis

Chief Financial Officer

Barbara Castellano

Partner

Lorenzo Giordano

CFO

Fabrizio Landi

Co-Founder & Managing Partner

Giacomo Piccinini

Associate

Alessio Piuma

Investment Manager

Diana Saraceni

Co-Founder & Managing Partner

Marco Sardina

Scientific Partner

Robbie Woodman

Partner

Past deals in Italy

MMI

Series B in 2022
MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Diadem

Venture Round in 2022
Diadem Srl is a drug development company based in Brescia, Italy, focused on addressing Alzheimer's disease. Founded in 2012, the company is dedicated to advancing innovative therapeutic solutions aimed at predicting and treating this complex neurodegenerative condition. Through its research and development efforts, Diadem seeks to improve the diagnosis and management of Alzheimer's, contributing to the broader fight against this challenging disease.

InnovHeart

Series C in 2022
InnovHeart s.r.l. manufactures transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease. The company offers Saturn TMVR system a mitral heart valve designed for trans-apical or trans-septal delivery systems. InnovHeart s.r.l. was founded in 2015 and is based in Milan, Italy with an additional office in Newton, Massachusetts.

InnovHeart

Series B in 2020
InnovHeart s.r.l. manufactures transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease. The company offers Saturn TMVR system a mitral heart valve designed for trans-apical or trans-septal delivery systems. InnovHeart s.r.l. was founded in 2015 and is based in Milan, Italy with an additional office in Newton, Massachusetts.

Endostart

Seed Round in 2018
Endostart is a developed a novel proprietary Magnetic Balloon Anchoring Technology.

Aileens Pharma

Series A in 2018
The company intends to use the funds to accelerate the development of its platform of topical non-steroidal treatments for atopic dermatitis both in children and adults, as well as other types of dermatological disorders.

MMI

Series A in 2018
MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Seventeen

Series A in 2016
Seventeen is a medtech startup. The company intends to use the funds to finalize the technology and clinically validate it in order to obtain the CE mark.

Echolight

Series A in 2016
Echolight S.r.l. is a research-based biomedical company based in Lecce, Italy, founded in 2011. The company specializes in developing non-invasive solutions for the early diagnosis of osteoporosis. Its flagship product, EchoS, is a radiation-free ultrasound device that assesses bone micro-architecture and enables the scanning of central bone sites. This innovative technology allows for accurate evaluation of bone mineral density (BMD) and provides an office-based service for the early detection and monitoring of osteoporosis. Echolight aims to enhance accessibility and accuracy in bone health assessments, catering to the needs of both clinicians and patients.